Pass and reprice answer different questions
A pass says that the opportunity does not work under the team’s investment logic even if price moves within a plausible range. A reprice says that the underlying case may work, but the current economics allocate too much risk to the buyer.
Confusing the two can destroy useful information. “Too expensive” is not the same diagnosis as “not investable.”
Common repricing conditions
- Growth uncertainty: the valuation assumes a trajectory the evidence does not yet support.
- Information discount: a key issue cannot be resolved before closing.
- Security disadvantage: the buyer is taking common-equity risk beneath a meaningful preference stack.
- Financing risk: future capital needs create dilution or down-round exposure.
- Duration risk: the likely liquidity horizon is longer than the quoted price implies.
- Execution asymmetry: the upside requires several things to go right while downside can arrive through one or two obvious paths.
When a lower price does not fix the deal
Some problems are structural. If the buyer cannot obtain required rights, the company is outside mandate, the key evidence is not trustworthy, or the investment thesis depends on an event the team cannot underwrite, “cheaper” may only create the illusion of discipline.
That is why ClarityInvest separates reprice from restructure and stop. Each route names a different binding constraint.
Make the reprice condition explicit
A useful reprice is not “we need 20% more discount.” It is a statement such as: “At the current information level and expected hold, the return only clears our hurdle below X,” or “If Y is confirmed, the current price can work; if not, the price must absorb that uncertainty.”
Key takeaway
Repricing is most useful when the asset thesis survives but the economics do not. Naming the reason for the reprice keeps the team from using price to disguise a broken thesis — or rejecting a good opportunity for an addressable economic problem.
Sources and notes
- Mercer, Private markets in motion: navigating secondaries — valuation factors beyond headline discount
- Lazard, Interim 2026 Secondary Market Report — pricing and underwriting discipline in 2026